These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 18348656

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer.
    Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A.
    Int J Biol Markers; 2010; 25(3):126-35. PubMed ID: 20872355
    [Abstract] [Full Text] [Related]

  • 25. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G.
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [Abstract] [Full Text] [Related]

  • 26. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH, Lin YS, Lin CC, Yang YH, Ho YP, Tsai CC.
    J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
    [Abstract] [Full Text] [Related]

  • 27. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.
    Bewick M, Conlon M, Gerard S, Lee H, Parissenti AM, Zhang L, Glück S, Lafrenie RM.
    Bone Marrow Transplant; 2001 Apr; 27(8):847-53. PubMed ID: 11477443
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Pantel K, Krenkel S, Lück HJ, Neumann R, Keller T, Dittmer J, Jänicke F, Thomssen C.
    Anticancer Res; 2006 Apr; 26(2B):1479-87. PubMed ID: 16619561
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma.
    Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S.
    Anticancer Res; 2000 Apr; 20(6B):4413-8. PubMed ID: 11205281
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T, Toi M, Tominaga T.
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
    Liu ZB, Liu GY, Yang WT, Di GH, Lu JS, Shen KW, Shen ZZ, Shao ZM, Wu J.
    Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.